Daniel Hägerstrand

About me
Publications
CV
Public outreach and news

About me

(2015) Magnus Bergvalls stiftelse
(2014) Magnus Bergvalls stiftelse
(2014) Karolinska Institutets Forskningsstiftelser
(2014) Best poster together with PhD student Min Guo at the Winterviken
retreat for the depart of Oncology-Pathology, KI
(2008-2009) Sweden-American foundation post doc scholarship, 300000 SEK
(2007-2013) Harvard Medical School, Department of Medical Oncology,
Dana-Farber Cancer Institute, William Hahn lab, Boston, USA
(2007) PhD in experimental tumor biology, Department of Oncology-Pathology,
Karolinska Institutet (KI), Cancer Center Karoliska (CCK) “Molecular
determinants of glioma subsets with distinct histology or sensitivity to
signal transduction inhibitors”, supervisor Professor Arne Östman,
Stockholm, Sweden
(2001) Master of Science in Biology at Uppsala University, Uppsala, Sweden

Articles

Article: LEUKEMIA. 2024;38(6):1287-1298

IκBε deficiency accelerates disease development in chronic lymphocytic leukemia

Bordini J; Lenzi C; Frenquelli M; Morabito A; Pseftogas A; Belloni D; Mansouri L; Tsiolas G; Perotta E; Ranghetti P; Gandini F; Genova F; Hagerstrand D; Gavriilidis G; Keisaris S; Pechlivanis N; Davi F; Kay NE; Langerak AW; Pospisilova S; Scarfo L; Makris A; Psomopoulos FE; Stamatopoulos K; Rosenquist R; Campanella A; Ghia P
Article: SCIENTIFIC REPORTS. 2022;12(1):9838

Altered cytoskeletal status in the transition from proneural to mesenchymal glioblastoma subtypes

Keller M; Blom M; Conze LL; Guo M; Hagerstrand D; Aspenstrom P
Article: CANCER REPORTS. 2022;5(5):e1498

The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells

Al-Qahtani SM; Gadalla SE; Guo M; Ericsson C; Hagerstrand D; Nister M
Article: ONCOGENE. 2021;40(32):5066-5080

SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma

Guo M; Goudarzi KM; Abedi S; Pieber M; Sjoberg E; Behnan J; Zhang X-M; Harris RA; Bartek J; Lindstrom MS; Nister M; Hagerstrand D
Article: GLIA. 2020;68(2):316-327

Astrocytes enhance glioblastoma growth

Mega A; Nilsen MH; Leiss LW; Tobin NP; Miletic H; Sleire L; Strell C; Nelander S; Krona C; Hagerstrand D; Enger PO; Nister M; Ostman A
Article: NEURO-ONCOLOGY ADVANCES. 2020;2(1):vdaa061

Identification of functionally distinct and interacting cancer cell subpopulations from glioblastoma with intratumoral genetic heterogeneity

Guo M; van Vliet M; Zhao J; de Stahl TD; Lindstrom MS; Cheng H; Heller S; Nister M; Hagerstrand D
Article: CLINICAL CANCER RESEARCH. 2019;25(12):3702-3717

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer

Sjoberg E; Meyrath M; Milde L; Herrera M; Lovrot J; Hagerstrand D; Frings O; Bartish M; Rolny C; Sonnhammer E; Andy CE; Augsten M; Ostman A
Article: CANCER RESEARCH. 2018;78(20):5901-5916

Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype

Goudarzi KM; Espinoza JA; Guo M; Bartek J; Nister M; Lindstrom MS; Hagerstrand D
Article: ONCOTARGET. 2017;8(49):84671-84684

Glioblastoma and glioblastoma stem cells are dependent on functional MTH1

Pudelko L; Rouhi P; Sanjiv K; Gad H; Kalderen C; Hoglund A; Squatrito M; Schuhmacher AJ; Edwards S; Hagerstrand D; Berglund UW; Helleday T; Brautigam L
Article: ONCOTARGET. 2016;7(45):72431-72442

PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status

Roodakker KR; Elsir T; Edqvist P-HD; Hagerstrand D; Carison J; Lysiak M; Henriksson R; Ponten F; Rosell J; Soderkvist P; Stupp R; Tchougounova E; Nister M; Malmstrom A; Smits A
Article: ONCOGENE. 2015;34(2):209-216

TRAF2 is an NF-κB-activating oncogene in epithelial cancers

Shen RR; Zhou AY; Kim E; O'Connell JT; Hagerstrand D; Beroukhim R; Hahn WC
Article: CANCER DISCOVERY. 2013;3(9):1044-1057

Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers

Hagerstrand D; Tong A; Schumacher SE; Ilic N; Shen RR; Cheung HW; Vazquez F; Shrestha Y; Kim SY; Giacomelli AO; Rosenbluh J; Schinzel AC; Spardy NA; Barbie DA; Mermel CH; Weir BA; Garraway LA; Tamayo P; Mesirov JP; Beroukhim R; Hahn WC
Article: NEURO-ONCOLOGY. 2011;13(11):1178-1191

Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile

Hagerstrand D; He X; Lindh MB; Hoefs S; Hesselager G; Ostman A; Nister M
Article: ANTI-CANCER DRUGS. 2010;21(8):759-765

Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents

Uecker A; Sicker M; Beckers T; Mahboobi S; Hagerstrand D; Ostman A; Bohmer F-D
Article: NEURO-ONCOLOGY. 2010;12(9):967-975

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541

Hagerstrand D; Lindh MB; Pena C; Garcia-Echeverria C; Nister M; Hofmann F; Ostman A
Article: NEURO-ONCOLOGY. 2008;10(1):2-9

Gene expression analyses of grade II gliomas and identification of rPTPβ/ζ as a candidate oligodendroglioma marker

Haegerstrand D; Smits A; Eriksson A; Sigurclarclottir S; Olofsson T; Hartman M; Nister M; Kalimo H; Oetman A
Article: ONCOGENE. 2006;25(35):4913-4922

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures

Hagerstrand D; Hesselager G; Achterberg S; Bolin UW; Kowanetz M; Kastemar M; Heldin C-H; Isaksson A; Nister M; Ostman A

All other publications

Corrigendum: ONCOGENE. 2021;40(32):5153

SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma (May, 10.1038/s41388-021-01825-2, 2021)

Guo M; Goudarzi KM; Abedi S; Pieber M; Sjoberg E; Behnan J; Zhang X-M; Harris RA; Bartek J; Lindstrom MS; Nister M; Hagerstrand D
Corrigendum: ONCOTARGET. 2020;11(8):827

Correction: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1.

Pudelko L; Rouhi P; Sanjiv K; Gad H; Kalderén C; Höglund A; Squatrito M; Schuhmacher AJ; Edwards S; Hägerstrand D; Berglund UW; Helleday T; Bräutigam L
Meeting abstract: CANCER RESEARCH. 2016;76:2385

Understanding the dynamic interplay between genetically different cancer cell clones in glioblastoma

Guo M; Heller S; Thorslund J; Orre L; Lehtio J; Nister M; Hagerstrand D
Meeting abstract: NEURO-ONCOLOGY. 2014;16:v122-v123

PRO-MIGRATORY AND -PROLIFERATIVE EFFECTS OF ASTROCYTES ON GBM CELLS

Mega A; Sleire L; Hagerstrand D; Enger PO; Nister M; Ostman A
Thesis / dissertation: 2007

Molecular determinants of glioma subsets with distinct histology or sensitivity to signal transduction inhibitors

Hägerstrand, Daniel

Employments

Senior Research Specialist, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2022-

Degrees and Education

Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2007

About me

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI